🔥🐔 BizChicken 🐔🔥
Companies Similar to CARGO Therapeutics, Inc. Common Stock
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
CARGO Therapeutics, Inc. Common Stock
CRG-022
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.
About | Leadership | Directors | About | Contact | Contact | Careers | Careers | Careers | Careers | About | About
Symbol: CRGX
Recent Price: $13.76
Industry: Biotechnology
CEO: Ms. Gina Chapman
Sector: Healthcare
Employees: 150
Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403
Phone: 650-379-6143
Leadership
- Gina Chapman, President and Chief Executive Officer
- Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
- Ginna Laport, MD, Chief Medical Officer
- Shishir Gadam, PhD, Chief Technical Officer
- Michael Ports, PhD, Chief Scientific Officer
- Kari Leetch, Chief People Officer
- Halley Gilbert, JD, Chief Legal Officer
- Bethany Rogers, SVP, Product Strategy and Commercialization
- Faisal Shawwa, SVP, Finance
- Tonia J. Buchholz, PhD, Head of Clinical Science
- Kanika Chawla, PhD, Head of Process Sciences
- Sandra Chen, Head of Clinical Quality and Risk Management
- Michelle Gray, Head of Clinical Operations
- Adam Haskett, Head of External Manufacturing
- David Hoffman, JD, Head of Intellectual Property & Transactions
- Anissa Irwin, Head of Quality Assurance and Systems
- Brett Masterson, Head of Marketing
- Rob McCombie, Head of CMC Regulatory
- Frank McDonald, Head of Clinical Data Management
- Priya Parameswaran, Head of Corporate Strategy and Business Operations
- Shabnum Patel, PHD, Head of MSAT
- Mary Rodley, Head of CMC Strategy and Operations
- Abhijeet Sarvaiya, Head of Statistical Programming
- Brian Schoelkopf, Head of FP&A
- Christophe Suchet, Head of IT
- Beth Vasievich, PhD, Head of Commercial Planning and Operations
- Jun Wang, Head of Procurement
- John Orwin, Chairman of the Board
- Abraham Bassan, Board Director
- Kapil Dhingra, M.B.B.S, Board Director
- Reid Huber, PHD, Board Director
- David Lubner, Board Director
- Krishnan Viswanadhan, Pharm.D, Board Director
- Jane Pritchett Henderson, Board Director
Last updated: 2024-12-31
Contineum Therapeutics, Inc. Class A Common Stock
PIPE-791
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Symbol: CTNM
Recent Price: $14.47
Industry: Biotechnology
CEO: Mr. Carmine N. Stengone MBA, MS
Sector: Healthcare
Employees: 31
Address: 10578 Science Center Drive, San Diego, CA 92121
Phone: (858) 333-5280
Leadership
- Carmine Stengone, President and Chief Executive Officer
- Austin Chen, PhD, Senior Vice President, Head of Research
- Beverly Dixon, Senior Director, Quality Assurance
- Kristina Haeckl, Sr. Vice President, Regulatory Affairs
- Daniel Lorrain, PhD, Chief Scientific Officer
- John Healy, General Counsel & Corporate Secretary
- Jon Seiders, PhD, Vice President, CMC
- Jules Lee, Senior Director, Clinical Operations
- Julie Iwashita, Vice President, Clinical Operations
- Karin Stebbins, Vice President, Toxicology
- Michael Mayberry, Vice President, Finance
- Mike Poon, PhD, Vice President, Biology
- Peter Slover, Chief Financial Officer
- Stephen Huhn, MD, Chief Medical Officer & Senior Vice President, Clinical Development
- Tara Vargas, Senior Director, Project Management
- Thomas O. Schrader, PhD, Senior Director, Chemistry
- Varsha Dourado, Vice President, Business Development
Last updated: 2024-12-31
CERo Therapeutics Holdings, Inc.
Engineered T Cell Therapeutics
CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment, particularly targeting hematologic malignancies using innovative immune system integration strategies.
Symbol: CERO
Recent Price: $0.06
Industry: Biotechnology
CEO: Mr. Christopher B. Ehrlich M.B.A.
Sector: Healthcare
Employees: 8
Address: 201 Haskins Way, South San Francisco, CA 94080
Phone: 650-407-2376
Last updated: 2024-12-31
Mustang Bio, Inc.
Gene and CAR T Cell Therapies
Mustang Bio, Inc. is a biopharmaceutical company specializing in cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. It focuses on developing gene therapy programs and CAR T cell therapies, including treatments for X-linked severe combined immunodeficiency and various types of cancer.
About | Leadership | Directors | News | Contact | About | About | Careers | About | About | Careers | About | About
Symbol: MBIO
Recent Price: $0.19
Industry: Biotechnology
CEO: Dr. Manuel Litchman M.D.
Sector: Healthcare
Employees: 80
Address: 377 Plantation Street, Worcester, MA 01605
Phone: 781 652 4500
Leadership
- Manuel Litchman, M.D., President, Chief Executive Officer and Director
- Greg Furrow, M.S., FRQA, Chief Quality Officer
- James Murphy, B.A., Ad interim Chief Financial Officer
- Michael S. Weiss, Chairman of the Board of Directors
- Lindsay A. Rosenwald, M.D., Director
- Adam J. Chill, Director
- Neil Herskowitz, Director
- Michael J. Zelefsky, M.D., Director
- Mustang Bio, Inc., Company
Last updated: 2024-12-31
Telomir Pharmaceuticals, Inc. Common Stock
TELOMIR-1
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.
Symbol: TELO
Recent Price: $4.64
Industry: Biotechnology
CEO: Mr. Erez Aminov
Sector: Healthcare
Employees: 1
Address: 855 N Wolfe Street, Baltimore, null 21205
Phone: (737)-289-0835
Last updated: 2024-12-31
Agenus Inc.
Retrocyte Display
Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.
Symbol: AGEN
Recent Price: $2.69
Industry: Biotechnology
CEO: Dr. Garo H. Armen Ph.D.
Sector: Healthcare
Employees: 389
Address: 3 Forbes Road, Lexington, MA 02421-7305
Phone: 781 674 4400
Last updated: 2024-12-31
Allogene Therapeutics, Inc.
UCART19
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
About | About | About | Contact | Contact | Careers | Careers | Jobs | About | About | About | About | About | About
Symbol: ALLO
Recent Price: $2.10
Industry: Biotechnology
CEO: Dr. David D. Chang M.D., Ph.D.
Sector: Healthcare
Employees: 232
Address: 210 East Grand Avenue, South San Francisco, CA 94080
Phone: 650 457 2700
Last updated: 2024-12-31
Cabaletta Bio, Inc.
DSG3-CAART
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its leading product, DSG3-CAART, is in Phase I trials for treating mucosal pemphigus vulgaris.
Symbol: CABA
Recent Price: $2.24
Industry: Biotechnology
CEO: Dr. Steven A. Nichtberger M.D.
Sector: Healthcare
Employees: 136
Address: 2929 Arch Street, Philadelphia, PA 19104
Phone: 267 759 3100
Leadership
- Steven Nichtberger, M.D., President, Chief Executive Officer, and Co-Founder
- Samik Basu, M.D., Chief Scientific Officer
- Gwendolyn Binder, Ph.D., President, Science & Technology
- David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer
- Arun Das, M.D., Chief Business Officer
- Michael Gerard, General Counsel
- Heather Harte-Hall, Chief Compliance Officer
- Anup Marda, Chief Financial Officer
- Martha O’Connor, Chief Human Resources Officer
- Sarah Yuan, Ph.D., Chief Technology Officer
- Catherine Bollard, M.D., Independent Director, George Washington University
- Scott Brun, M.D., Independent Director, formerly at AbbVie
- Richard Henriques, M.B.A., Independent Director, former CFO of Gates Foundation, former Controller at Merck
- Mark Simon, M.B.A., Independent Director, Torreya Partners
- Shawn Tomasello, M.B.A., Independent Director, former CCO of Kite Pharma, Inc.
Last updated: 2024-12-31
Carisma Therapeutics, Inc.
chimeric antigen receptors (CAR) macrophages
Carisma Therapeutics, Inc. is a biopharmaceutical company that develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors, leveraging advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy.
Symbol: CARM
Recent Price: $0.44
Industry: Biotechnology
CEO: Mr. Steven Kelly
Sector: Healthcare
Employees: 107
Address: 3675 Market St., Philadelphia, PA 19104
Phone: 484 899 0326
Leadership
- Steven Kelly, President & CEO
- Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer
- Eugene Kennedy, MD, Chief Medical Officer
- Kenneth Locke, Senior Vice President, Technical Operations
- Richard Morris, Chief Financial Officer
- Terry Shields, Senior Vice President, Human Resources
- Eric Siegel, General Counsel and Corporate Secretary
- Tom Wilton, Chief Business Officer
- Sascha Abramson, PhD, Vice President, Scientific Operations
- Heather Ansorge, PhD, VP, Program and Portfolio Management
- Thomas Condamine, PhD, Vice President, Discovery and Translational Sciences
Last updated: 2024-12-31
Celularity Inc.
CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.
About | Leadership | Directors | About | About | About | About | Directors | Careers | About | About | About | About | About | About
Symbol: CELU
Recent Price: $2.05
Industry: Biotechnology
CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
Sector: Healthcare
Employees: 120
Address: 170 Park Avenue, Florham Park, NJ 07932
Phone: 908 768 2170
Leadership
- Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
- David Beers, CFA, Chief Financial Officer
- Stephen Brigido, DPM, President, Degenerative Diseases
- John Haines, Global Manager and Chief Administrative Officer
- K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
- John Colerangle, DVM, Ph.D., Regulatory Affairs
- Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
- Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
- Carmine Palummo, Corporate Operations
- Tim Wilk, Technical Operations
- Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
- Peter Diamandis, M.D., Director
- Dean Kehler, Director
- Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
- Diane Parks, Director
Last updated: 2024-12-31
Cellectar Biosciences, Inc.
CLR 131
Cellectar Biosciences, Inc. is a clinical biopharmaceutical company concentrating on the development and commercialization of drugs for cancer treatment.
Symbol: CLRB
Recent Price: $0.29
Industry: Biotechnology
CEO: Mr. James V. Caruso
Sector: Healthcare
Employees: 20
Address: 100 Campus Drive, Florham Park, NJ 07932
Phone: 608 441 8120
Leadership
- James Caruso, President, CEO and Director
- Chad Kolean, Chief Financial Officer
- Shane Lea, Chief Commercial Officer
- Jarrod Longcor, Chief Operating Officer
- Andrei Shustov, Senior Vice President, Medical
- Douglas J. Swirsky, Chairman of the Board
- Asher Alban Chanan-Khan, MD., Director
- Frederick W. Driscoll, Director
- Stefan D. Loren, Ph.D., Director
- John Neis, Director
- Cellectar Biosciences, Inc., Company Information
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Caribou Biosciences, Inc.
CB-010, CB-011, CB-012, CB-020
Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.
About | About | Contact | Contact | Careers | Jobs | Benefits | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Careers | About | About | Vision/Values | DEI | Benefits
Symbol: CRBU
Recent Price: $1.61
Industry: Biotechnology
CEO: Dr. Rachel E. Haurwitz Ph.D.
Sector: Healthcare
Employees: 158
Address: 2929 7th Street, Berkeley, CA 94710
Phone: 510 982 6030
Last updated: 2024-12-31
Design Therapeutics, Inc.
Gene TAC
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes products targeting Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as Gene TAC candidates for other similar diseases.
About | Contact | Careers | About | About | About | About | About | News | About | Careers | About
Symbol: DSGN
Recent Price: $6.17
Industry: Biotechnology
CEO: Mr. Pratik Shah Ph.D.
Sector: Healthcare
Employees: 57
Address: 6005 Hidden Valley Road, Carlsbad, CA 92011
Phone: 858 293 4900
Last updated: 2024-12-31
Foghorn Therapeutics Inc.
Gene Traffic Control platform
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. It utilizes its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Symbol: FHTX
Recent Price: $4.61
Industry: Biotechnology
CEO: Mr. Adrian H. B. Gottschalk
Sector: Healthcare
Employees: 116
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 586 3100
Leadership
- Steven Bellon, PHD, Chief Scientific Officer
- Carlos Costa, Chief People Officer
- Danette Daniels, PHD, VP, Protein Degrader Platform
- Dan Dinu, MBA, VP, Information Technology
- Michael Garcia-Webb, PHD, VP, Chief of Staff Research
- Andrew Germain, PHD, VP, Legal
- Adrian Gottschalk, President & CEO
- Chong-Hui Gu, PHD, VP, CMC and QA
- Karin Hellsvik, Chief of Staff to the CEO Vice President, Corporate Affairs and Investor Relations
- Murphy Hentemann, PHD, VP, Program Leadership
- Kristian Humer, MBA, Chief Financial Officer
- Michael LaCascia, Chief Legal Officer
- Marina Nelen, PhD, VP, Drug Discovery
- Alfonso Quintás-Cardama, MD, Chief Medical Officer
- Alena Reva, VP, Total Rewards & People Operations
- Anna Rivkin, PHD, Chief Business Officer
- Saurabh Sewak, PHD, VP, Corporate Development
- Gromek Smolen, PHD, VP, Biology
- Kevin Wilson, PHD, VP, Chemistry
- José Baselga MD, PhD, In Memoriam
- Scott Biller, PHD, Strategic Advisor, Agios Pharmaceuticals
- Doug Cole, MD, Founder, Foghorn Therapeutics Managing Partner, Flagship Pioneering
- Simba Gill, PhD, Former President & CEO, Evelo Biosciences
- Cigall Kadoch, PhD, Scientific Advisor to the Board of Directors; Founder, Foghorn Therapeutics
- Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences
- Tom Lynch, MD, President and Director, Fred Hutchinson Cancer Center
- Michael Mendelsohn, MD, Chairman & Founder, Cardurion Pharmaceuticals
- Lynne Parshall, Senior Strategic Advisor, Ionis Pharmaceuticals
- Ian Smith, Chairman of the Board, Solid BioSciences
- Gerald Crabtree, MD, Founder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute
- Tony Kouzarides, PhD, FMedSci, FRS, Professor of Cancer Biology at the University of Cambridge Director of the Milner Therapeutics Institute and Deputy Director of the Gurdon Institute
- Charles Sawyers, MD, Investigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; SAB Chair
- David Schenkein, MD, General Partner, Co-leader, Google Ventures life science team Former CEO, Agios
Last updated: 2024-12-31
Regulus Therapeutics Inc.
RG-012 and RGLS8429
Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.
Symbol: RGLS
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Sector: Healthcare
Employees: 30
Address: 4224 Campus Point Court, San Diego, CA 92121
Phone: 858 202 6300
Last updated: 2024-12-31
TRACON Pharmaceuticals, Inc.
therapeutics for cancer
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.
Symbol: TCON
Recent Price: $0.03
Industry: Biotechnology
CEO: Mr. Craig R. Jalbert CIRA
Sector: Healthcare
Employees: 17
Address: 4350 La Jolla Village Drive, San Diego, CA 92122
Phone: 858 550 0780
Last updated: 2024-12-31
TScan Therapeutics, Inc.
T cell receptor-engineered T cell therapies
TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.
About | About | Management | Directors | About | About | Contact | Careers | Careers | Careers | About | About
Symbol: TCRX
Recent Price: $3.00
Industry: Biotechnology
CEO: Dr. Gavin MacBeath Ph.D.
Sector: Healthcare
Employees: 175
Address: 830 Winter Street, Waltham, MA 02451
Phone: 857 399 9500
Leadership
- Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
- Katina Dorton, J.D., M.B.A., CFO of Nodthera
- Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
- Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
- Gavin MacBeath, Ph.D., CEO of TSCAN
- Garry Nicholson, Former President of Pfizer Oncology
- R. Keith Woods, Former Chief Operating Officer of argenx
Last updated: 2024-12-31
Cadrenal Therapeutics, Inc. Common Stock
Tecarfarin
Cadrenal Therapeutics, Inc. is a clinical development biopharmaceutical company focusing on novel therapies for preventing systemic thromboembolism in patients with specific health conditions, headquartered in Ponte Vedra, Florida.
Symbol: CVKD
Recent Price: $14.23
Industry: Biotechnology
CEO: Mr. Quang X. Pham
Sector: Healthcare
Employees: 4
Address: 822 A1A North, Ponte Vedra, FL 32082
Phone: 904 300 0701
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31